Acetylcysteine - Zambon

Drug Profile

Acetylcysteine - Zambon

Alternative Names: Fluimucil; Flumil; NSC 111180; Rinofluimucil

Latest Information Update: 09 Aug 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Zambon Group SpA
  • Developer Elder Pharmaceuticals; Inpharzam Ricerche S.A.; Sermmitr; Zambon Company SpA
  • Class Antibronchitics; Expectorants; Reducing agents; Small molecules; Sulfur amino acids
  • Mechanism of Action Free radical inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary fibrosis

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease; Common cold; Poisoning
  • Discontinued HIV infections; Pulmonary fibrosis; Renal failure

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 09 Aug 2010 Discontinued - Phase-III for Pulmonary fibrosis in European Union (PO)
  • 29 Sep 2004 Data presented at the 14th Annual Congress of the European Respiratory Society (ERS-2004) have been added to the Respiratory Tract Disorders therapeutic trials section ,,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top